EP 1505985 A1 20050216 - COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS
Title (en)
COMBINATION THERAPY FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISEASES IN PATIENTS AT RISK OF THROMBOTIC CARDIOVASCULAR EVENTS
Title (de)
KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON CYCLOOXYGENASE-2-VERMITTELTEN ERKRANKUNGEN BEI PATIENTEN MIT ERHÖHTEM RISIKO FÜR THROMBOTISCHE KARDIOVASKULÄRE EREIGNISSE
Title (fr)
THERAPIE DE COMBINAISON DESTINEE A TRAITER DES MALADIES A MEDIATION PAR CYCLOOXYGENASE-2 CHEZ DES MALADES PRESENTANT UN RISQUE D'ACCIDENT CARDIOVASCULAIRE THROMBOTIQUE
Publication
Application
Priority
- US 0314778 W 20030509
- US 38866002 P 20020510
Abstract (en)
[origin: WO03094924A1] The present invention encompasses a method for treating a chronic cyclooxygenase-2 mediated disease or condition and reducing the risk of a thrombotic cardiovascular event in a human patient in need of such treatment and at risk of a thrombotic cardiovascular event comprising orally concomitantly or sequentially administering to said patient a cyclooxygenase-2 selective inhibitor in an amount effective to treat the cyclooxygenase-2 mediated disease or condition and nitric oxide releasing aspirin in an amount effective to reduce the risk of the thrombotic cardiovascular event while maintaining a high level of upper gastrointestinal safety and tolerability. The invention also encompasses a method for treating a chronic cyclooxygenase-2 mediated disease or condition and reducing the risk of a thrombotic cardiovascular event in a human patient in need of such treatment and at risk of a thrombotic cardiovascular event comprising orally concomitantly or sequentially administering to said patient a nitric oxide releasing- cyclooxygenase-2 selective inhibitor in an amount effective to treat the cyclooxygenase-2 mediated disease or condition and aspirin in an amount effective to reduce the risk of the thrombotic cardiovascular event while maintaining a high level of upper gastrointestinal safety and tolerability. Pharmaceutical compositions are also encompassed.
IPC 1-7
A61K 31/60; A61K 31/50; A61K 31/4418; A61K 31/42; A61K 31/415; A61K 31/341; A61K 31/196
IPC 8 full level
A61K 45/06 (2006.01)
CPC (source: EP)
A61K 45/06 (2013.01)
Citation (search report)
See references of WO 03094924A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 03094924 A1 20031120; AU 2003229005 A1 20031111; EP 1505985 A1 20050216
DOCDB simple family (application)
US 0314778 W 20030509; AU 2003229005 A 20030509; EP 03726785 A 20030509